{
    "organizations": [],
    "uuid": "ba5b92b75113db74432f2376f1bc3149da03bff2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-axs-02-in/brief-axsome-therapeutics-says-axs-02-independent-data-monitoring-committee-recommends-continuation-of-coast-1-trial-idUSFWN1P40CV",
    "ord_in_thread": 0,
    "title": "BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 9, 2018 / 12:25 PM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial Reuters Staff 1 Min Read \nJan 9 (Reuters) - Axsome Therapeutics Inc: \n* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL \n* AXSOME THERAPEUTICS- IN CREATE-1 TRIAL, AXS-02 TREATMENT RESULTED IN SIGNIFICANT REDUCTION OF SERUM CTX AS COMPARED TO PLACEBO \n* AXSOME THERAPEUTICS- IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION IN BOTH STUDIES, CONFIRMED THAT AXS-02 WAS SAFE AND GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage:",
    "published": "2018-01-09T14:23:00.000+02:00",
    "crawled": "2018-01-09T14:41:10.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "say",
        "independent",
        "data",
        "monitoring",
        "committee",
        "recommends",
        "continuation",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "axsome",
        "therapeutic",
        "inc",
        "axsome",
        "therapeutic",
        "announces",
        "independent",
        "data",
        "monitoring",
        "committee",
        "recommends",
        "continuation",
        "trial",
        "discontinuation",
        "trial",
        "axsome",
        "trial",
        "treatment",
        "resulted",
        "significant",
        "reduction",
        "serum",
        "ctx",
        "compared",
        "placebo",
        "axsome",
        "idmc",
        "also",
        "reviewed",
        "available",
        "safety",
        "information",
        "study",
        "confirmed",
        "safe",
        "generally",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}